Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release

doi:10.1016/S0741-8329(96)00069-9

Alcohol

Volume 13, Issue 6, November–December 1996, Pages 569-574

https://doi.org/10.1016/S0741-8329(96)00069-9 Get rights and content

Abstract

The effects of local application of the 5-HT₃ receptor agonist, 1-(m-chlorophenyl)-biguanide (CPBG), and IP administration of ethanol on the extracellular levels of dopamine (DA) in the ventral tegmental area (VTA) were studied using in vivo microdialysis. Adult female Wistar rats were implanted with microdialysis probes in the VTA at least 24 h before each experiment. Stable extracellular levels of DA (101 ± 9 fmol/20 min) were established before initiating the experiments. Application of 10–250 μM CPBG through the microdialysis probe dosedependently enhanced the extracellular concentrations of DA but did not alter the levels of either 3,4-dihydroxyphenylacetic acid or homovanillic acid in the dialysate. The effects of CPBG were reversible and dependent upon Ca²⁺. Co-perfusion with the 5-HT₃ receptor antagonist, 3-tropanyl-indole-3-carboxylate (ICS 205-930), inhibited the effects of CPBG on enhancing extracellular DA levels. The IP administration of 2g/kg ethanol significantly (p < 0.005) enhanced the levels of DA to 150% of baseline values; this ethanol-induced increase was prevented by local perfusion with 100 μM ICS 205–930. These results suggest that 5-HT₃ receptors in the VTA are involved in regulating the somatodendritic release of DA and in mediating the stimulatory effects of ethanol on this neuronal system.

References (40)

J.N. Barnes et al.
Characterization and autoradiographic localization of 5-HT₃ receptor recognition sites identified with [³H]-(S)-zacopride in the forebrain of the rat
Neuropharmacology
(1990)
N. Bonhomme et al.
Evidence for 5-HT₄ receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: A microdialysis study in the halothane-anesthetized rats
Neuropharmacology
(1995)
M.S. Brodie et al.
Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro
Brain Res.
(1990)
A.D. Campbell et al.
Serotonin₃ receptor and ethanol-stimulated dopamine release in the nucleus accumbens
Pharmacol. Biochem. Behav.
(1995)
E. Carboni et al.
Differential inhibitory effects of a 5-HT₃ antagonist on drug-induced stimulation of dopamine release
Eur. J. Pharmacol.
(1989)
D.R. Gehlert et al.
Localization of 5-HT₃ receptors in the rat brain using [³H] LY278584
Brain Res.
(1991)
G.L. Gessa et al.
Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area
Brain Res.
(1985)
K.A. Grant
The role of 5-HT₃ receptors in drug dependence
Drug Alcohol Depend.
(1995)
X.-M. Guan et al.
Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release
Brain Res. Bull.
(1989)
G.M. Halliday et al.
Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum
Brain Res. Bull.
(1989)

D. Herve et al.

Serotonin axon terminals in the ventral tegmental area of the rat: Fine structure and synaptic input to dopaminergic neurons

Brain Res.

(1987)

R.L. Klein et al.

Effects of 5-HT₃ receptor antagonists on binding and function mouse and human GABA_A receptors

Eur. J. Pharmacol.

(1994)

G.J. Kilpatrick et al.

1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT₃ receptor agonist

Eur. J. Pharmacol.

(1990)

D.J. Knapp et al.

Zacopride, a 5-HT₃ receptor antagonist, reduces voluntary ethanol consumption in rats

Pharmacol. Biochem. Behav.

(1992)

Y. Minabe et al.

The 5-HT₃ receptor antagonists LY277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells

Eur. J. Pharmacol.

(1991)

A. Parent et al.

Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [³H]-5-hydroxytryptamine

Neuroscience

(1981)

K.W. Perry et al.

Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum

Life Sci.

(1992)

M. Pessia et al.

Actions of 5-hydroxytrptamine on ventral tegmental area neurons of the rat in vitro

Brain Res.

(1994)

L.A. Phebus et al.

Brain anoxia releases striatal dopamine in rats

Life Sci.

(1986)

K. Rasmussen et al.

The 5-HT₃ receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons

Eur. J. Pharmacol.

(1991)

Cited by (107)

The role of brain serotonin signaling in excessive alcohol consumption and withdrawal: A call for more research in females
2024, Neurobiology of Stress
Alcohol Use Disorder (AUD) is a leading cause of death and disability worldwide, but current treatments are insufficient in fully addressing the symptoms that often lead to relapses in alcohol consumption. The brain's serotonin system has been implicated in AUD for decades and is a major regulator of stress-related behaviors associated with increased alcohol consumption. This review will discuss the current literature on the association between neurobiological adaptations in serotonin systems and AUD in humans as well as the effectiveness of serotonin receptor manipulations on alcohol-related behaviors like consumption and withdrawal. We will further discuss how these findings in humans relate to findings in animal models, including a comparison of systemic pharmacological manipulations modulating alcohol consumption. We next provide a detailed overview of brain region-specific roles for serotonin and serotonin receptor signaling in alcohol-related behaviors in preclinical animal models, highlighting the complexity of forming a cohesive model of serotonin function in AUD and providing possible avenues for more effective therapeutic intervention. Throughout the review, we discuss what is known about sex differences in the sequelae of AUD and the role of serotonin in these sequelae. We stress a critical need for additional studies in women and female animals so that we may build a clearer path to elucidating sex-specific serotonergic mechanisms and develop better treatments.
A ghrelin receptor antagonist reduces the ability of ghrelin, alcohol or amphetamine to induce a dopamine release in the ventral tegmental area and in nucleus accumbens shell in rats
2021, European Journal of Pharmacology
The orexigenic peptide ghrelin increases the release of dopamine in the nucleus accumbens (NAc) shell via central ghrelin receptors, especially those located in the ventral tegmental area (VTA). The activity of the VTA dopamine neurons projecting to NAc shell, involves somatodendritic dopamine release within the VTA. However, the effects of ghrelin on the concomitant dopamine release in the VTA and NAc shell is unknown. It is further unknown whether addictive drugs, such as alcohol and amphetamine, enhance the dopamine levels in both these areas via ghrelin receptor dependent mechanisms. Thus, the effects of a ghrelin receptor antagonist, JMV2959, on the ability of i) central ghrelin ii) systemic alcohol or iii) systemic amphetamine to increase the dopamine release in the VTA and in the NAc shell in rats by using in vivo microdialysis was explored. We showed that systemic administration of JMV2959 blocks the ability of central ghrelin to increases dopamine release in the VTA and the NAc shell, and reduces the alcohol- and amphetamine-induced dopamine release in both these areas. Locomotor activity studies was then conducted in an attempt to correlate the ghrelin-induced dopamine release in the VTA to a behavioural outcome. These revealed that local infusion of a dopamine D₁ receptor antagonist into the VTA blocks the ability of central ghrelin to cause a locomotor stimulation in mice. Collectively, this study adds to the growing body of evidence indicating that ghrelin signalling modulates the ability of ghrelin, and addictive drugs, to activate the mesoaccumbal dopamine pathway.
Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence
2021, Progress in Brain Research
Citation Excerpt :
Briefly, they proposed that 5-HT3 receptor antagonists were preferentially inhibiting the rise of DA release sustained by an increase in the electrical activity of DA neurons such as the one occurring with nicotine, haloperidol, morphine, but not cocaine and amphetamine (Carboni et al., 1989). These results have been largely confirmed (Campbell and McBride, 1995; Campbell et al., 1996; Carboni et al., 1989; De Deurwaerdere et al., 2005; Porras et al., 2003; Volonte et al., 1995) although some data suggest that 5-HT3 receptor antagonists could reduce cocaine-stimulated extracellular levels of DA (Kankaanpaa et al., 1996, 2002; McNeish et al., 1993). The state-dependent excitatory influence of 5-HT3 receptors on DA release is preferential in the Nac compared to the striatum (Volonte et al., 1995).
The interaction between serotonin (5-HT) and dopamine (DA) in the central nervous system (CNS) plays an important role in the adaptive properties of living animals to their environment. These are two modulatory, divergent systems shaping and regulating in a widespread manner the activity of neurobiological networks and their interaction. The concept of one interaction linking these two systems is rather elusive when looking at the mechanisms triggered by these two systems across the CNS. The great variety of their interacting mechanisms is in part due to the diversity of their neuronal origin, the density of their fibers in a given CNS region, the distinct expression of their numerous receptors in the CNS, the heterogeneity of their intracellular signaling pathway that depend on the cellular type expressing their receptors, and the state of activity of neurobiological networks, conditioning the outcome of their mutual influences. Thus, originally conceptualized as inhibition of 5-HT on DA neuron activity and DA neurotransmission, this interaction is nowadays considered as a multifaceted, mutual influence of these two systems in the regulation of CNS functions. These new ways of understanding this interaction are of utmost importance to envision the consequences of their dysfunctions underlined in several CNS diseases. It is also essential to conceive the mechanism of action of psychotropic drugs directly acting on their function including antipsychotic, antidepressant, antiparkinsonian, and drug of abuse together with the development of therapeutic strategies of Alzheimer's diseases, epilepsy, obsessional compulsive disorders. The 5-HT/DA interaction has a long history from the serendipitous discovery of antidepressants and antipsychotics to the future, rationalized treatments of CNS disorders.
Agmatine reverses ethanol consumption in rats: Evidences for an interaction with imidazoline receptors
2019, Pharmacology Biochemistry and Behavior
Alcohol is one of the most widely abused recreational drugs, largely linked with serious health and social concerns. However, the treatment options for alcohol-use disorders have limited efficacy and exhibit a range of adverse drug reactions. Large numbers of preclinical studies have projected a biogenic amine, agmatine as a promising potential treatment option for drug addiction, including alcoholism. In the present study, administration of agmatine (20–40 mg/kg, i.p.) resulted in significant inhibition of ethanol self-administration in the right p-VTA in operant conditioning paradigm. Further, acute intracranial administration of agmatine (20 and 40 μg/rat) significantly reduced the ethanol consumption in the two bottle choice paradigm. Agmatine is degraded to putrescine and guanido-butanoic acid by the enzyme agmatinase and diamine oxidase respectively and inhibition of these enzymes results in augmentation of endogenous agmatine. In the present study, diamine oxidase inhibitor, aminoguanidine and agmatinase inhibitor, arcaine were used to block the agmatine metabolic pathways to increase brain agmatine levels. Drugs that augment endogenous agmatine levels like L-arginine (80 μg/rat, i.c.v.) or arcaine (50 μg/rat, i.c.v.) and aminoguanidine (25 μg/rat, i.c.v.) also reduced the ethanol consumption following their central administration. The pharmacological effect of agmatine on ethanol consumption was potentiated by imidazoline receptor agonists, I₁ agonist moxonidine (25 μg/rat, i.c.v.), and imidazoline I₂ agonist, 2-BFI (10 μg/rat, i.c.v.) and was blocked by imidazoline I₁ antagonist, efaroxan (10 μg/rat, i.c.v.), and I₂ antagonist, idazoxan (4 μg/rat, i.c.v.) at their ineffective doses per se. Thus, our result suggests the involvement of imidazoline I₁ and I₂ receptors in agmatine induced inhibition of ethanol consumption in rats.
Dorsal Raphe Dual Serotonin-Glutamate Neurons Drive Reward by Establishing Excitatory Synapses on VTA Mesoaccumbens Dopamine Neurons
2019, Cell Reports
Dorsal raphe (DR) serotonin neurons provide a major input to the ventral tegmental area (VTA). Here, we show that DR serotonin transporter (SERT) neurons establish both asymmetric and symmetric synapses on VTA dopamine neurons, but most of these synapses are asymmetric. Moreover, the DR-SERT terminals making asymmetric synapses on VTA dopamine neurons coexpress vesicular glutamate transporter 3 (VGluT3; transporter for accumulation of glutamate for its synaptic release), suggesting the excitatory nature of these synapses. VTA photoactivation of DR-SERT fibers promotes conditioned place preference, elicits excitatory currents on mesoaccumbens dopamine neurons, increases their firing, and evokes dopamine release in nucleus accumbens. These effects are blocked by VTA inactivation of glutamate and serotonin receptors, supporting the idea of glutamate release in VTA from dual DR SERT-VGluT3 inputs. Our findings suggest a path-specific input from DR serotonergic neurons to VTA that promotes reward by the release of glutamate and activation of mesoaccumbens dopamine neurons.
Early post-natal neuroactive steroid manipulation modulates ondansetron effects on initial periods of alcohol consumption in rats
2018, Physiology and Behavior
Neuroactive steroids (NS) such as allopregnanolone are crucial for brain development and adult behaviour. Early post-natal alterations of NS by administering finasteride induce a decrease in the sensitivity to stimulant effects of low alcohol doses, an increase in alcohol consumption, and a decrease in ventrostriatal dopamine and serotonin levels. The aim of the present study is to observe if the effects of the 5HT3 receptor antagonist ondansetron on initial alcohol consumption are modulated by post-natal NS manipulation. For this purpose, allopregnanolone, finasteride, or vehicle was injected from day 5 to 9. In adulthood, a novel object preference test was carried out in order to detect a possible novelty-seeking pattern in our animals, which has been related to vulnerability to drug abuse. The subjects then had access to two bottles (alcohol or control solutions) one hour daily for two consecutive weeks. Ondansetron (0.01 mg/kg, 0.1 mg/kg or vehicle) was administered before the hour of consumption in the initial phase (days 1, 2, 3) of the procedure, and after prolonged alcohol intake (days 11, 12, 13). Results indicated that finasteride animals showed a higher preference to explore the new object, as well as a higher alcohol consumption than the rest of the groups. Moreover, 0.1 mg/kg of ondansetron decreased alcohol consumption, but only in the post-natal finasteride group, suggesting a possible increase in 5HT3 receptor sensitivity in these animals. In conclusion, NS manipulation in crucial stages of development, such as early post-natal periods, seems to play an important role on the effects of ondansetron on alcohol intake and in the vulnerability to develop drug use or abuse.

View all citing articles on Scopus

View full text

ArticleSerotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release

Abstract

Neuropharmacology

Neuropharmacology

Brain Res.

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Brain Res.

Brain Res.

Drug Alcohol Depend.

Brain Res. Bull.

Brain Res. Bull.

Brain Res.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Pharmacol. Biochem. Behav.

Eur. J. Pharmacol.

Neuroscience

Life Sci.

Brain Res.

Life Sci.

Eur. J. Pharmacol.

Article
Serotonin-3 receptor and ethanol-stimulated somatodendritic dopamine release